Supplementary Figure S2 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Q: What type of study is this?

This is a RCT study (also classified as: Phase 2).

Chang Gon Kim; Min Hee Hong; Dahee Kim; Brian Hyohyoung Lee; Hyunwook Kim; Chan‐Young Ock; Geoffrey Kelly; Yoon Ji Bang; Gamin Kim; Jung Eun Lee; Chaeyeon Kim; Se‐Heon Kim; Hyun Jun Hong; Young Min Park; Nam Suk Sim; Heejung Park; Jin Woo Park; Chang Geol Lee; Kyung Hwan Kim; Goeun Park; Inkyung Jung; Dawoon Han; Jong Hoon Kim; Junha Cha; Insuk Lee; Mingu Kang; Heon Song; Chiyoon Oum; Seulki Kim; Sukjun Kim; Yoojoo Lim; Seunghee Kim‐Schulze; Miriam Mérad; Sun Och Yoon; Hyun Je Kim; Yoon Woo Koh; Hye Ryun Kim

doi:10.1158/1078-0432.29996676

Key Points

Durvalumab combined with tremelimumab improved T cell marker expression in patients.
AI-powered analysis revealed distinct immune phenotypes based on Cancer Genome Atlas data.
Observational analysis utilized artificial intelligence to assess immune responses in head and neck cancer.
Findings highlight the potential for tailored immunotherapies in specific immune phenotypes.

Implication

Open-label trial analyzed T cell markers in patients with head and neck squamous cell carcinoma, suggesting immune phenotype variations.

Abstract

Expression of T cell markers according to immune phenotypes based on artificial intelligence-powered analysis using the Cancer Genome Atlas Head-Neck Squamous Cell Carcinoma cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2025) studied this question.

synapsesocial.com/papers/68bb3a352b87ece8dc954d4b https://doi.org/10.1158/1078-0432.29996676

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S2 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading